Study protocol of an open-label prospective phase ii umbrella study of precise neoadjuvant therapy for patients with stage ii-iiib resectable non-small cell lung cancer (purpose)

HIGHLIGHTS

• who: Yiyang Wang and collaborators from the National Research Council (CNR), Italy Peking University People`s Hospital have published the research work: Study protocol of an open-label prospective phase II umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE), in the Journal: (JOURNAL) of October/26,/2021
• what: In the EASTERN trial, objective response rate (ORR) was 42.1% for patients with stage IIA (N2) NSCLC treated by erlotinib . This study design allows opening up to additional cohorts so that patients with these gene . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.